Maverick Capital’s Collegium Pharmaceutical COLL Stock Holding History

Maverick Capital’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-39,596	Closed	-$1.27M	–	257
2024 Q2	$1.27M	Buy	39,596 +30,723	+346%	+$1.07M	0.02%	181
2024 Q1	$344K	Buy	+8,873	New	+$310K	0.01%	313
2023 Q3	–	Sell	-10,401	Closed	-$224K	–	350
2023 Q2	$224K	Sell	10,401 -895	-8%	-$20.3K	﹤0.01%	384
2023 Q1	$271K	Buy	11,296 +555	+5%	+$14.7K	0.01%	428
2022 Q4	$249K	Sell	10,741 -3,991	-27%	-$80.5K	0.01%	338
2022 Q3	$236K	Buy	+14,732	New	+$260K	0.01%	287
2021 Q3	–	Sell	-33,751	Closed	-$798K	–	668
2021 Q2	$798K	Buy	+33,751	New	+$780K	0.01%	340
2021 Q1	–	Sell	-6,926	Closed	-$139K	–	737
2020 Q4	$139K	Buy	+6,926	New	+$135K	﹤0.01%	559
2019 Q2	–	Sell	-395,080	Closed	-$5.98M	–	290
2019 Q1	$5.98M	Buy	+395,080	New	+$6.33M	0.08%	154
2018 Q4	–	Sell	-421,993	Closed	-$6.22M	–	269
2018 Q3	$6.22M	Sell	421,993 -2,597	-0.6%	-$46K	0.08%	146
2018 Q2	$10.1M	Buy	+424,590	New	+$10.4M	0.12%	80

Other funds holding COLL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Maverick Capital's COLL Position: Q3 2024 in Review

Maverick Capital sold out of Collegium Pharmaceutical (COLL) in Q3 2024, closing a stake of 39,596 shares — an estimated $1.27M sold.

Maverick Capital first reported a position in COLL in Q2 2018 and held it in 11 quarters. The position peaked at $10.1M in Q2 2018. 249 funds tracked by Wall St. Rank hold COLL as of Q3 2024.

Maverick Capital reported no remaining Collegium Pharmaceutical position as of Q3 2024 after selling out during the quarter.
Maverick Capital sold 39,596 Collegium Pharmaceutical shares in Q3 2024, an estimated $1.27M.
Maverick Capital first reported a position in Collegium Pharmaceutical in Q2 2018 and held it in 11 quarters.
Maverick Capital's Collegium Pharmaceutical position peaked at $10.1M in Q2 2018.
249 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2024.

Based on Maverick Capital's 13F filing for Q3 2024, filed 14 Nov 2024.